Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    17077333 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: recombinant human thrombopoietin (rhTPO); dexamethasone;   Drug: Dexamethasone
2 Completed Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Intervention: Drug: rhTPO in combination with Rituximab
3 Completed High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Prednisone;   Drug: Dexamethasone
4 Withdrawn Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: recombinant human thrombopoietin (rhTPO); rituximab;   Drug: Dexamethasone
5 Not yet recruiting Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone
Conditions: ITP;   Croticosteroid Therapy
Interventions: Drug: High dose Dexamethasone pulses;   Drug: Prednisone
6 Completed rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: rituximab; recombinant human thrombopoietin (rhTPO);   Drug: Rituximab

Study has passed its completion date and status has not been verified in more than two years.